PDCD1 and small cell lung carcinoma: Leramilimab in combination with spartalizumab (anti-PD-1 mAb) was well tolerated and showed initial antitumor activity in patients with mesothelioma and triple-negative BC, neuroendocrine tumors, small cell lung cancer (SCLC), and DLBCL.